drugset / Trial / NCT03257761
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
Phase 1
Active not recruiting
55 enrolled
University of Southern California
National Cancer Institute (NCI) · collabVan Andel Research Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase Ib trial studies the side effects and best dose of guadecitabine and how well it works when given together with durvalumab in treating patients with liver, pancreatic, bile duct, or gallbladder cancer that has spread to other places in the body. Guadecitabine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as durvalumab, may block tumor growth in different ways by targeting certain cells. Giving guadecitabine and durvalumab may work better in treating patients with liver, pancreatic, bile duct, or gallbladder cancer.
Timeline
- Start
- 2018-02-07
- Primary completion
- 2021-09-27
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | Guadecitabine | Oligonucleotide (other) | — | Subcutaneous |